Regeneron Science Talent Search finalists press on at a time of uncertainty March 07, 2025Vol.51 No.09By Yiqing Wang
Drugs & Targets FDA accepts review for odronextamab BLA in r/r follicular lymphoma February 28, 2025Vol.51 No.08
Clinical Roundup Interim results of phase II study shows survival benefit of THIO in NSCLC September 13, 2024Vol.50 No.34
High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forwardNCI’s Youth Enjoy Science (YES) program also invests in student scientists June 28, 2024Vol.50 No.26By McKenzie Prillaman
Clinical Roundup REGN7075 + Libtayo leads to anti-tumor responses in MSS colorectal cancer in dose-escalation portion of phase I/II study May 31, 2024Vol.50 No.22
Clinical Roundup Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data April 12, 2024Vol.50 No.15
